| Literature DB >> 29885541 |
Cristina Belizna1, Ljudmila Stojanovich2, Jan Willem Cohen-Tervaert3, Céline Fassot4, Daniel Henrion4, Laurent Loufrani4, Gyorgy Nagy5, Christian Muchardt6, Milena Hasan7, Marie Noelle Ungeheuer8, Laurent Arnaud9, Jaume Alijotas-Reig10, Enrique Esteve-Valverde11, Ferdinando Nicoletti12, Patrick Saulnier13, Alban Godon14, Pascal Reynier15, Jean Marie Chrétien13, Laura Damian16, Loukman Omarjee17, Guillaume Mahé17, Marc Antoine Pistorius18, Pier Luigi Meroni19, Katrien Devreese20.
Abstract
Primary antiphospholipid syndrome (PAPS) and antiphospholipid syndrome associated to lupus (SAPS) have several overlapping characteristics. As systemic manifestations are also reported in patients with PAPS, and as a subgroup of PAPS patients could evaluate to a SAPS, the differentiation between the two types of APS could be performed based on the clinical experience of the medical teams and is related to a variety of clinical, biological, histological and genetic features. Several data are available in the literature with respect to the identification of distinctive features between these two entities. However, there are some limitation in the interpretation of results issued from studies performed prior to updated Sydney criteria. Based on recent data, a certain number of features more frequent in one type of APS as compared to the other could be distinguished. The major differentiation between these two entities is genetical. New genetic data allowing the identification of specific subgroups of APS are ongoing.Entities:
Keywords: Antiphospholipid syndrome; Primary antiphospholipid syndrome; Secondary antiphospholipid syndrome
Mesh:
Substances:
Year: 2018 PMID: 29885541 DOI: 10.1016/j.autrev.2018.01.027
Source DB: PubMed Journal: Autoimmun Rev ISSN: 1568-9972 Impact factor: 9.754